title: A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.
abstract: The efficacy and toxicity of carboplatin plus mitoxantrone in blast crisis of chronic myeloid leukemia (CMLBC) were evaluated. Between 1990 and 1996, 20 patients (11 males and nine females, median age of 49 years [range 30-75 years]) were treated with carboplatin, 250 mg/m(2)/day x 5 days as an infusion and mitoxantrone, 10 mg/m(2)/day x 3 days, IV bolus. Median time from diagnosis of CML to BC was 4.25 years (range 0-11 years). CMLBC was myeloid in 13 patients, lymphoid in six, and megakaryocytic in one. All patients were Philadelphia (Ph) chromosome positive; four had a single Ph chromosome, five had double Ph chromosome, three had abnormalities of chromosome 17, and eight had complex cytogenetic abnormalities. Prior treatment for chronic phase included hydroxyurea (12 patients), interferon-alpha (11 patients), cytarabine or all-trans retinoic acid, three patients each and other agents (four patients). Eight patients (five myeloid and three lymphoid) had an objective response (median duration, 3 months). Five had complete responses (CR) of 2, 3, 3, 6, and 6+ months duration, and three had partial responses (PR) for 1, 2, and 4 months. Seven patients died too early to evaluate (TETE): three died pancytopenic in <30 days from initiation of chemotherapy, two patients had pancytopenia for >30 days but had only blasts in their day 30 bone marrow, and two patients were pancytopenic >30 days but demonstrated trilineage marrow regeneration. Three of eight responders survived > or =1 year. Toxicity was primarily hematologic. The objective response rate was 61% (8/13) among those who did not die TETE and 40% among all treated patients. Carboplatin plus mitoxantrone are highly active in CMLBC, with marrow aplasia as the dose-limiting toxicity, and these agents deserve further study in CMLBC, perhaps in combination with tyrosine kinase inhibitors.
authors.affiliation: New York Medical College, 600 East 233rd Street, Bronx, NY 10466, USA. jpd4401@aol.com
authors.forename: Janice P
authors.initials: JP
authors.lastname: Dutcher
authors.forename: Evelyn L
authors.initials: EL
authors.lastname: Morris
authors.forename: Bruce
authors.initials: B
authors.lastname: Gaynor
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Paietta
authors.forename: Peter H
authors.initials: PH
authors.lastname: Wiernik
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D015465:Leukemia, Myeloid, Accelerated Phase / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D010198:Pancytopenia / Q000139:chemically induced; D010865:Pilot Projects; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D008942:Mitoxantrone
references.citation: Leukemia. 1992 Aug;6(8):770-5
references.pmid: 1379312
references.citation: Blood. 2007 Apr 15;109(8):3207-13
references.pmid: 17185463
references.citation: N Engl J Med. 2002 Feb 28;346(9):645-52
references.pmid: 11870241
references.citation: J Natl Compr Canc Netw. 2008 Mar;6 Suppl 2:S31-S36
references.pmid: 18397679
references.citation: Cancer. 1988 Aug 15;62(4):672-6
references.pmid: 3165046
references.citation: Leukemia. 2006 Mar;20(3):400-3
references.pmid: 16437142
references.citation: Haematologica. 2003 Nov;88(11):1213-20
references.pmid: 14607749
references.citation: Ann Intern Med. 1999 Aug 3;131(3):207-19
references.pmid: 10428738
references.citation: Br J Haematol. 2002 Sep;118(4):1048-54
references.pmid: 12199784
references.citation: Cancer. 2007 Mar 1;109(5):899-906
references.pmid: 17236224
references.citation: Haematologica. 2009 May;94(5):743-4
references.pmid: 19407320
references.citation: J Clin Oncol. 1998 Oct;16(10):3279-85
references.pmid: 9779702
references.citation: Cancer. 2007 Apr 15;109(8):1543-9
references.pmid: 17340589
references.citation: Blood. 1993 Aug 1;82(3):691-703
references.pmid: 8338938
references.citation: J Clin Oncol. 1984 Apr;2(4):329-35
references.pmid: 6368762
references.citation: Haematologica. 1997 Sep-Oct;82(5):604-5
references.pmid: 9407733
references.citation: Leukemia. 2008 Dec;22(12):2176-83
references.pmid: 18754032
references.citation: Am J Med. 1987 Sep;83(3):445-54
references.pmid: 3477958
references.citation: Haematologia (Budap). 2002;32(1):49-57
references.pmid: 12243555
references.citation: Int J Hematol. 2008 Mar;87(2):167-171
references.pmid: 18288566
references.citation: Haematologica. 2008 Dec;93(12):1792-6
references.pmid: 18838477
references.citation: Leukemia. 1992 Oct;6(10):1072-5
references.pmid: 1405761
references.citation: N Engl J Med. 2001 Apr 5;344(14):1038-42
references.pmid: 11287973
references.citation: Leuk Lymphoma. 2007 Feb;48(2):283-9
references.pmid: 17325887
references.citation: Cancer Treat Rep. 1982 Feb;66(2):267-71
references.pmid: 6173123
references.citation: Biometrics. 1985 Sep;41(3):741-4
references.pmid: 4074823
references.citation: J Clin Oncol. 1998 Apr;16(4):1526-31
references.pmid: 9552062
references.citation: Neoplasma. 2001;48(3):203-7
references.pmid: 11583290
references.citation: Leukemia. 1998 Jul;12(7):1037-40
references.pmid: 9665187
references.citation: Cancer. 1988 Apr 1;61(7):1441-6
references.pmid: 3162181
references.citation: Ann Hematol. 1996 Nov;73(5):225-30
references.pmid: 8959940
references.citation: Leukemia. 1990 Nov;4(11):755-7
references.pmid: 2232887